The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to publics.

675+

Collective years of investing and operational experience

100

Portfolio companies

61

M&A and IPOs

32

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2020 (NASDAQ:ARQT)
Acquired by Blueprint Medicines in 2021
IPO in 2019 (NASDAQ: PHAT)
Acquired by CutisPharma in 2019
IPO in 2020 (NASDAQ: TARS)
Acquired by Sanofi in 2021
Acquired by Pfizer in 2021

Life Sciences News

Lengo Therapeutics

Blueprint Medicines Completes Acquisition of Lengo Therapeutics

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund

Frazier Life Sciences Team

Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

Frazier Life Sciences Team

Frazier Healthcare Partners Adds Highly Experienced Biopharmaceutical Executive to Life Sciences Team

View All News